Table 2 Mortality rates by potential baseline risk factors

Sex

Male

422

69

8.0 (6.3; 10.2)

Female

1031

128

5.7 (4.8; 6.8)

Age

≤ 30

251

41

8.7 (6.4; 11.8)

31 to 40

670

83

5.8 (4.7; 7.2)

> 40

532

73

6.2 (4.9; 7.7)

WHO stage

I

20

1

2.3 (0.3; 16.0)

II

642

55

3.8 (2.9; 5.0)

III

673

109

7.8 (6.5; 9.4)

IV

118

32

14.9 (10.5; 21.0)

Baseline CD4 count cells/mm³

<50

444

110

13.0 (10.8; 15.6)

50-99

232

20

3.9 (2.5; 6.0)

100 - 149

306

33

4.9 (3.5; 6.9)

150 - 199

339

21

2.8 (1.8; 4.2)

≥ 200

132

13

4.5 (2.6; 7.7)

Baseline plasma viral load copies/ml

<1,000

21

3

6.7 (2.2; 20.7)

1,000 - 9,999

40

2

2.6 (0.6; 10.3)

10,000 -99,999

454

49

4.9 (3.7; 6.5)

100,000 -999,999

832

130

7.4 (6.3; 8.8)

>1,000,000

106

13

5.7 (3.3; 9.9)

Weight (kg) *

< 50

431

94

11.0 (9.0; 13.4)

50 - 60

698

76

5.0 (4.0; 6.3)

> 60

317

22

3.0 (2.0; 4.6)

Haemoglobin (g/dl)

≥ 11

701

76

5.0 (4.0; 6.3)

9.5 - 10.9

407

64

7.4 (5.8; 9.5)

8.0 - 9.4

242

37

7.4 (5.3; 10.2)

6.5 - 7.9

80

12

6.7 (3.8; 11.7)

<6.5

19

6

19.2 (8.6; 42.8)

Missing

4

2

On cotrimoxazole prophylaxis

Yes

1403

185

6.2 (5.3; 7.1)

No

50

12

12.0 (6.8; 21.1)

Study Arm

Facility Based

594

80

6.5 (5.2; 8.1)

Home Based

859

117

6.3 (5.2; 7.5)

Time following initiating ART

0 - 5 months

1453

112

16.5 (13.7; 19.8)

6 - 11 months

1296

42

6.7 (5.0; 9.1)

12 - 23 months

1168

32

3.0 (2.2; 4.3)

24 - 35 months

872

8

1.3 (0.7; 2.6)

≥ 36 months

314

3

2.4 (0.8; 7.6)